reports
- Hilde Van Boxstael
- Kristof Samoy
- Lynn Hautekeete
- Michiel Declercq
- Thibault Leneeuw
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
RESULTATS ANNUELS 2025
RESULTATS ANNUELS 2025 INFORMATION RÉGLEMENTÉEBruxelles, 11 février 2026, 17h55 DES RÉSULTATS 2025 SOLIDES CONFIRMANT LA STRATÉGIE DE NEXTENSA Nextensa a clôturé l’exercice financier 2025 avec des résultats solides, confirmant une nette amélioration de sa rentabilité (+€ 33,8 M), portée par une contribution accrue des activités de développement (+€ 1,8 M), la baisse des coûts de financement (-€ 9,2 M) et la poursuite du renforcement du bilan. Au cours des exercices 2024 et 2025, Nextensa a réalisé plusieurs transactions ciblées pour un montant total de € 360 M. Grâce à cette approch...
JAARRESULTATEN 2025
JAARRESULTATEN 2025 GEREGLEMENTEERDE INFORMATIEBrussel, 11 februari 2026, 17u55 STERKE RESULTATEN OVER 2025 BEVESTIGEN DE STRATEGIE VAN NEXTENSA Nextensa sloot het boekjaar 2025 af met sterke resultaten, waarmee een duidelijke stijging van de winstgevendheid werd bevestigd (+€ 33,8 M), gedreven door een hogere bijdrage van de ontwikkelingsactiviteiten (+€ 1,8 M), lagere financieringskosten (-€ 9,2 M) en een verdere versterking van de balans. In 2024 en 2025 realiseerde Nextensa meerdere gerichte transacties voor een totaalbedrag van € 360 M. Als rechtstreeks gevolg van deze gediscipl...
ANNUAL RESULTS 2025
ANNUAL RESULTS 2025 REGULATED INFORMATIONBrussels, 11 February 2026, 5:55 PM STRONG FULL-YEAR 2025 RESULTS CONFIRM NEXTENSA’S STRATEGIC COURSE Nextensa closed the 2025 financial year with strong results, confirming a clear increase in profitability (+€33.8 M) driven by a higher contribution from development activities (+1.8 M), lower financing costs (-9.2 M) and a continued balance sheet strengthening. During 2024 and 2025, Nextensa executed several targeted transactions for a total amount of €360 M. As a direct outcome of this disciplined capital recycling approach, Nextensa reduced...
- Arancha Pineiro
AHOLD DELHAIZE: RDOS. 4T'25 (ANÁLISIS BANCO SABADELL)
Rdos. 4T'25 vs 4T'24: Ventas: 23.490 M euros (+0,9% vs +0,8% BS(e) y +0,4% consenso); EBIT: 994,0 M euros (+3,8% vs -4,3% BS(e) y -4,2% consenso); BDI: 577,0 M euros (+51,8% vs +55,3% BS(e) y +57,4% consenso); Rdos. 2025 vs 2024: Ventas: 92.352 M euros (+3,4% vs +3,3% BS(e) y +3,2% consenso); EBIT: 3.734 M euros (+3,5% vs +1,4% BS(e) y +1,4% consenso); BDI: 2.263 M euros (+28,3% vs +29,0% BS(e) y +29,5% consenso).
- Research Department
INFORME DIARIO 11 FEBRERO + RDOS. ESPAÑA Y EUROPA 4T’25. IDEAS DESTACA...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: ENDESA, INDRA, SANTANDER, SECTOR SEGUROS, TELEFÓNICA. EUROPA: AHOLD DELHAIZE, BAYER. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 4T’25 que se publicarán en España y Europa en los próximos días. El Ibex mantiene los 18.100 puntos Ligeras caídas en los mercados en una jornada de transición a la espera de l...
Inventiva to Present at the Guggenheim Emerging Outlook: Biotech Summi...
Inventiva to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 Daix (France), New York (United States), February 4, 2025 – (Euronext Paris and NASDAQ: ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that CEO Andrew Obenshain has been invited to participate in a fireside chat at the upcoming Guggenheim Emerging Outlook: Biotech Summit 2026. The conference is being held February 11-12, 2026 at the Lotte New Yor...
Inventiva présentera au Guggenheim Emerging Outlook : Biotech Summit 2...
Inventiva présentera au Guggenheim Emerging Outlook : Biotech Summit 2026 Daix (France), New York (États-Unis), le 4 février 2026 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), a annoncé aujourd’hui que son Directeur général, Andrew Obenshain, a été invité à participer à un « fireside chat » lors du prochain Guggenheim Emerging Outlook: Biotech Summit 2026. La conférence se tiendra le...
- Guy Sips
- Jacob Mekhael
- Mathijs Geerts Danau
- Wim Hoste
- Wim Lewi
- Wim Lewi
Elia Group German government agrees on 25.1% Tennet stake
Yesterday, the German government (via KfW) secured a 25.1% "blocking minority" in TenneT's German operations. The €3.3bn deal ends years of negotiations between Germany and the Netherlands. The deal is struck at the same equity value following the capital contribution (46%) from ABP, GIC and Norges Bank in 09/25 at a total equity value of 13.3bn. TenneT NL will hold the remaining 28.9%. We understand from the Handelsblatt that KfW will invest an additional €1.7bn before 2035. TenneT GE will no...
- Dirk Verbiesen
- Quirijn Mulder
Arcadis/Slow start to FY26 but a better second half/HOLD
As 3Q25 showed only 1% organic growth, this did not translate into the anticipated pick-up in growth rates. We expect meagre organic growth to continue into FY26 as we foresee only 1.8%, with 1H26 likely being slower than 2H26. New management has been taking measures to reduce overhead costs. These cost savings are material, but will only come fully to fruit in FY27, also the year when we foresee a return to stronger organic growth. With consensus in our view still too optimistic on organic grow...
Nextensa NV/SA: Information on the total number of voting rights an...
Nextensa NV/SA: Information on the total number of voting rights and shares Nextensa NV/SA: Information on the total number of voting rights and shares In application of article 15 of the Law of 2 May 2007 on disclosure of major shareholdings, Nextensa (the 'Company') announces the following information following the loss of double voting rights attached to registered shares. Situation on 29 January 2026: Total capital : EUR 111,856,017.40 Total number of securities carrying voting rights: 10,171,130Number of securities with double voting rights: 6,174,488(1) Total numbe...
Nextensa SA: Informations relatives au nombre total de droits de vo...
Nextensa SA: Informations relatives au nombre total de droits de vote et d'actions Nextensa SA: Informations relatives au nombre total de droits de vote et d'actions En application de l'article 15 de la loi du 2 mai 2007 relative à la publicité des participations importantes, Nextensa (la ‘Société’) communique les informations suivantes suite à la perte des droits de vote double attachés aux actions nominatives. Situation au 29 janvier 2026 : Total du capital : EUR 111 856 017,40 Nombre total de titres conférant le droit de vote : 10 171 130 Nombre de tit...
Nextensa NV: Informatie betreffende het totale aantal stemrechten e...
Nextensa NV: Informatie betreffende het totale aantal stemrechten en aandelen Nextensa NV: Informatie betreffende het totale aantal stemrechten en aandelen In toepassing van artikel 15 van de wet van 2 mei 2007 op de openbaarmaking van belangrijke deelnemingen, maakt Nextensa (de ‘Vennootschap’) de volgende informatie bekend naar aanleiding van het verlies van het dubbel stemrecht verbonden aan aandelen op naam. Situatie op 29 januari 2026: Totaal kapitaal: EUR 111.856.017,40 Totaal aantal stemrechtverlenende effecten : 10.171.130 Aantal effecten met dubbel stemrecht :...
- Nicolas David
LOGI LOGITECH INTERNATIONAL S.A.
SGE SAGE GROUP PLC
DGE DIAGEO PLC
MC LVMH MOET HENNESSY LOUIS VUITTON SE
KPN ROYAL KPN NV
VOLV B VOLVO AB CLASS B
RI PERNOD RICARD SA
SSAB A SSAB AB CLASS A
RCO REMY COINTREAU SA
LONN LONZA GROUP AG
SAND SANDVIK AB
GLE SOCIETE GENERALE S.A. CLASS A
OMV OMV AG
ARCAD ARCADIS NV
STR STRABAG SE
AD KONINKLIJKE AHOLD DELHAIZE N.V.
ASML ASML HOLDING NV
CPR DAVIDE CAMPARI-MILANO N.V.
ATCO A ATLAS COPCO AB
- Nicolas David
LOGI LOGITECH INTERNATIONAL S.A.
SGE SAGE GROUP PLC
DGE DIAGEO PLC
MC LVMH MOET HENNESSY LOUIS VUITTON SE
KPN ROYAL KPN NV
VOLV B VOLVO AB CLASS B
RI PERNOD RICARD SA
SSAB A SSAB AB CLASS A
RCO REMY COINTREAU SA
LONN LONZA GROUP AG
SAND SANDVIK AB
GLE SOCIETE GENERALE S.A. CLASS A
OMV OMV AG
ARCAD ARCADIS NV
STR STRABAG SE
AD KONINKLIJKE AHOLD DELHAIZE N.V.
ASML ASML HOLDING NV
CPR DAVIDE CAMPARI-MILANO N.V.
ATCO A ATLAS COPCO AB
- Martijn Den Drijver
- Guy Sips
- Kristof Samoy
- Livio Luyten
- Lynn Hautekeete
- Michiel Declercq
- Wim Lewi
- Wim Lewi
Elia Group AI investment tsunami whips up TSO valuations
We upgrade our recommendation to Accumulate and raise our price target to €135.0 from €110.0 on multiple expansion over the next 6 to 12 months. We leave our EPS estimates for FY26-27 unchanged, but increase our price target to 22x FY27 EPS. Our previous target was based on 20x FY26 EPS, but we roll forward on a 10% higher multiple as the sentiment towards grid operators benefits from the “wall of money” into datacenters, while grid connection is the bottleneck. It can take years before the ROE ...
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvre...
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux Daix (France), New York City (New York, United States), January 26, 2026 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the half-year report of its liquidity contract with Kepler Cheuvreux. Under the liquidity contract granted to Kepler Cheuvreux by Inventiva, the following resou...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.